Hélène Vanacker

418 total citations
33 papers, 226 citations indexed

About

Hélène Vanacker is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, Hélène Vanacker has authored 33 papers receiving a total of 226 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 6 papers in Reproductive Medicine. Recurrent topics in Hélène Vanacker's work include Sarcoma Diagnosis and Treatment (15 papers), CAR-T cell therapy research (6 papers) and Ovarian cancer diagnosis and treatment (6 papers). Hélène Vanacker is often cited by papers focused on Sarcoma Diagnosis and Treatment (15 papers), CAR-T cell therapy research (6 papers) and Ovarian cancer diagnosis and treatment (6 papers). Hélène Vanacker collaborates with scholars based in France, United States and Egypt. Hélène Vanacker's co-authors include Isabelle Ray‐Coquard, Mehdi Brahmi, Armelle Dufresne, Jean‐Yves Blay, Franck Tirode, Daniel Pissaloux, Christophe Caux, Sophie Janssens, Jessica Vetters and Marie‐Cécile Michallet and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Hélène Vanacker

28 papers receiving 224 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hélène Vanacker France 9 99 87 54 37 34 33 226
Alona Meir Israel 8 55 0.6× 37 0.4× 49 0.9× 67 1.8× 15 0.4× 14 294
Rebecca Waters United States 8 73 0.7× 103 1.2× 78 1.4× 13 0.4× 14 0.4× 35 251
Danielle C. Costigan United States 9 83 0.8× 51 0.6× 52 1.0× 100 2.7× 18 0.5× 14 276
Rihai Xiao China 8 115 1.2× 56 0.6× 113 2.1× 12 0.3× 7 0.2× 21 287
Ann Tipps United States 8 53 0.5× 85 1.0× 48 0.9× 17 0.5× 10 0.3× 18 197
Annick Chevalier-Place France 6 48 0.5× 56 0.6× 33 0.6× 61 1.6× 12 0.4× 7 148
Vanja Filipovski North Macedonia 9 58 0.6× 43 0.5× 77 1.4× 32 0.9× 59 1.7× 21 307
Shashi Lele United States 8 31 0.3× 66 0.8× 54 1.0× 43 1.2× 6 0.2× 17 233
Naïri Tchrakian Canada 7 27 0.3× 50 0.6× 36 0.7× 20 0.5× 9 0.3× 12 145
Jana Drozenová Czechia 8 34 0.3× 66 0.8× 49 0.9× 45 1.2× 5 0.1× 29 202

Countries citing papers authored by Hélène Vanacker

Since Specialization
Citations

This map shows the geographic impact of Hélène Vanacker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hélène Vanacker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hélène Vanacker more than expected).

Fields of papers citing papers by Hélène Vanacker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hélène Vanacker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hélène Vanacker. The network helps show where Hélène Vanacker may publish in the future.

Co-authorship network of co-authors of Hélène Vanacker

This figure shows the co-authorship network connecting the top 25 collaborators of Hélène Vanacker. A scholar is included among the top collaborators of Hélène Vanacker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hélène Vanacker. Hélène Vanacker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vanacker, Hélène, Nicolas Penel, Sarah Watson, et al.. (2025). Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study. Cancer. 131(18). e70052–e70052. 1 indexed citations
2.
Vanacker, Hélène, et al.. (2025). Cellular therapies in sarcoma and other solid tumors. Current Opinion in Oncology. 37(4). 365–371.
3.
Vanacker, Hélène, Mehdi Brahmi, Daniel Pissaloux, et al.. (2025). Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing. ESMO Open. 10(9). 105555–105555.
4.
Corbaux, Pauline, Armelle Vinceneux, Hélène Vanacker, et al.. (2024). Patients’ selection and trial matching in early-phase oncology clinical trials. Critical Reviews in Oncology/Hematology. 196. 104307–104307. 5 indexed citations
5.
Terret, C., Camille Schiffler, Hélène Vanacker, et al.. (2024). Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial. Clinical Cancer Research. 30(10). 2111–2120. 3 indexed citations
6.
Vanacker, Hélène, Isabelle Treilleux, Camille Schiffler, et al.. (2024). p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British Journal of Cancer. 130(4). 613–619.
7.
8.
Dufresne, Armelle, et al.. (2023). Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond. Cancers. 15(6). 1643–1643. 11 indexed citations
9.
Bini, Marta, Justine Gantzer, Armelle Dufresne, et al.. (2023). ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases. JCO Precision Oncology. 7(7). e2300130–e2300130. 4 indexed citations
10.
Dufresne, Armelle, Daniel Pissaloux, Carine Ngo, et al.. (2023). Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors. ESMO Open. 8(2). 101202–101202. 10 indexed citations
11.
Brahmi, Mehdi, Armelle Dufresne, Hélène Vanacker, et al.. (2023). 1975P Systemic therapy for KIT/PDGFRA wild-type GIST. Annals of Oncology. 34. S1054–S1054. 4 indexed citations
12.
Chvetzoff, Gisèle, Bénédicte Mastroïanni, Hélène Vanacker, et al.. (2022). Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative study. BMJ Open. 12(4). e060317–e060317. 2 indexed citations
13.
Vanacker, Hélène, Daniel Pissaloux, Philippe A. Cassier, et al.. (2022). Expanding the molecular spectrum of tenosynovial giant cell tumors. Frontiers in Oncology. 12. 1012527–1012527. 9 indexed citations
14.
Vanacker, Hélène, Armelle Vinceneux, Emmanuelle Nicolas‐Virelizier, Mehdi Brahmi, & Philippe A. Cassier. (2021). Anticorps bispécifiques ciblant CD3 en oncologie solide et onco-hématologie. Bulletin du Cancer. 108(10). S181–S194. 3 indexed citations
15.
Brahmi, Mehdi, Isabelle Treilleux, Daniel Pissaloux, et al.. (2020). Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History. Cancers. 12(9). 2604–2604. 25 indexed citations
16.
Ray‐Coquard, Isabelle, Hélène Vanacker, Olivia Le Saux, & Olivier Trédan. (2020). Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?. EBioMedicine. 61. 103046–103046. 6 indexed citations
17.
Brahmi, Mehdi, Hélène Vanacker, Lauriane Eberst, et al.. (2020). Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial. Translational Oncology. 13(12). 100870–100870. 8 indexed citations
18.
Vanacker, Hélène, et al.. (2020). Rare ovarian tumors: an update on diagnosis and treatment. International Journal of Gynecological Cancer. 30(6). 879–887. 15 indexed citations
19.
Vanacker, Hélène, et al.. (2017). Emerging Role of the Unfolded Protein Response in Tumor Immunosurveillance. Trends in cancer. 3(7). 491–505. 30 indexed citations
20.
Vanacker, Hélène, et al.. (2015). [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].. Bulletin du Cancer. 102(6). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alona Meir Breakdown of academic impact, for papers by Rebecca Waters Breakdown of academic impact, for papers by Danielle C. Costigan Breakdown of academic impact, for papers by Rihai Xiao Breakdown of academic impact, for papers by Ann Tipps Breakdown of academic impact, for papers by Annick Chevalier-Place Breakdown of academic impact, for papers by Vanja Filipovski Breakdown of academic impact, for papers by Shashi Lele Breakdown of academic impact, for papers by Naïri Tchrakian Breakdown of academic impact, for papers by Jana Drozenová
Rankless by CCL
2026